Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Arora, Paul ^a,b   Garcia Bailo, Bibiana ^a,b   Dastani, Zari ^c   Brenner, Darren ^a,b   Villegas, Andre ^a   Malik, Suneil ^a   Spector, Timothy D ^d   Richards, Brent ^c   El Sohemy, Ahmed ^b   Karmali, Mohamed ^a,b   Badawi, Alaa ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN RECEPTOR, HUMAN; C-REACTIVE PROTEIN RECEPTOR, HUMAN; CHOLESTEROL; CYTOKINE; IL1A PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; SERUM AMYLOID A; TLR4 PROTEIN, HUMAN; TRIACYLGLYCEROL; VITAMIN D BINDING PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; GENETICS; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; METABOLISM; STATISTICAL MODEL; TWINS; UNITED KINGDOM;

ACUTE-PHASE PROTEINS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CROSS-SECTIONAL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; IMMUNITY, INNATE; INSULIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LINEAR MODELS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; SERUM AMYLOID A PROTEIN; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES; VITAMIN D-BINDING PROTEIN;

EID: 79960565557     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-95     Document Type: Article

References (65)

1. Wild S, Rolic C, Green A. Global prevalence of diabetes: Estimates for the year 2000 and projection for 2030. Diabetes Care 2004, 37:1047-1053.
2. Mokdad AH, Bowman BA, Ford ES, Vinicoor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001, 286:1195-1200.
3. Venkataraman R, Nanda NC, Baweja G, Parikh N, Bhatia V. Prevalence of diabetes mellitus and related conditions in Asian Indians living in the United States. Am J Cardiol 2004, 94:977-980. 10.1016/j.amjcard.2004.06.048, 15464696.
4. Stumvoll M, Goldstein B, van Haeften T. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346. 10.1016/S0140-6736(05)61032-X, 15823385.
5. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002, 90:27G-33G. 10.1016/S0002-9149(02)02556-0, 12231076.
6. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003, 88:2422-2429. 10.1210/jc.2003-030178, 12788837.
7. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7. 10.1016/j.it.2003.10.013, 14698276.
8. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787. 10.1038/414782a, 11742409.
9. Alberti KG. Treating type 2 diabetes - today's targets, tomorrow's goals. Diabetes Obes Metab 2001, 3(Suppl 1):3-10.
10. Pickup JC, Matttock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292. 10.1007/s001250050822, 9389420.
11. Pickup JC, Crook MA. Is Type II diabetes mellitus a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248. 10.1007/s001250051058, 9794114.
12. Beutler B. Innate immunity: an overview. Mol Immunol 2004, 40:845-859. 10.1016/j.molimm.2003.10.005, 14698223.
13. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9. 10.1016/j.smim.2003.10.003, 14751757.
14. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000, 343:338-344. 10.1056/NEJM200008033430506, 10922424.
15. Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch Physiol Biochem 2009, 115:176-190. 10.1080/13813450903079314, 19671019.
16. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006, 444:860-867. 10.1038/nature05485, 17167474.
17. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184. 10.1172/JCI29881, 1716210, 17200717.
18. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23. 10.2337/db06-1076, 17192460.
19. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415. 10.1172/JCI117936, 295872, 7738205.
20. Le Souef PN. Gene-environmental interaction in the development of atopic asthma: new developments. Curr Opin Allergy Clin Immunol 2009, 9:123-127. 10.1097/ACI.0b013e3283292283, 19295429.
21. Badawi A, Klip A, Haddad P, Cole DEC, Garcia Bailo B, El-Sohemy A, et al. Type 2 Diabetes Mellitus and Inflammation: Prospects for Biomarkers of Risk and Nutritional Intervention. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:173-186.
22. Spector TD, Williams FM. The UK Adult Twin Registry (TwinsUK). Twin Res Hum Genet 2006, 9:899-906. 10.1375/twin.9.6.899, 17254428.
23. The UK Adult Twin Registry. 2010, Ref Type: Internet Communication.
24. Andrew T, Hart DJ, Snieder H, de LM, Spector TD, MacGregor AJ. Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. Twin Res 2001, 4:464-477. 10.1375/1369052012803, 11780939.
25. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141. 10.1038/ng.507, 20037589.
26. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006, 55:2915-2921. 10.2337/db06-0600, 17003362.
27. Kubaszek SA, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom L, Eriksson J, et al. Finnish diabetes prevention study: promoter polymorphisms of the TNF-a (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2003, 52:1872-1876. 10.2337/diabetes.52.7.1872, 12829659.
28. Hoffstedt J, Eriksson P, Rossner S, Ryden PAM. Excessive fat accumulation is associated with the TNF a-308 G/A promoter polymorphism in women but not in men. Diabetologia 2000, 43:117-120. 10.1007/s001250050015, 10672452.
29. Susa S, Daimon M, Sakabe J, Sato H, Oizumi T, Karasawa S, et al. A functional polymorphism of the TNF-alpha gene that is associated with type 2 DM. Biochem Biophys Res Commun 2008, 369:943-947. 10.1016/j.bbrc.2008.02.121, 18328809.
30. Rasmussen SK, Urhammer SA, Jensen JN, Hansen T, Borch-Johnsen K, Pedersen O. The -238 and -308 G>A polymorphisms of the tumor necrosis factor a gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 2000, 85:1731-1734. 10.1210/jc.85.4.1731, 10770222.
31. Zeggini E, Groves CJ, Parkinson JR, Halford S, Owen KR, Frayling TM, et al. Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologia 2005, 48:2013-2017. 10.1007/s00125-005-1902-4, 16132956.
32. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007, 50:1115-1122. 10.1016/j.jacc.2007.06.012, 17868801.
33. Obisesan TO, Leeuwenburgh C, Ferrell RE, Phares DA, McKenzie JA, Prior SJ, et al. C-reactive protein genotype affects exercise training-induced changes in insulin sensitivity. Metabolism 2006, 55:453-460. 10.1016/j.metabol.2005.10.006, 2643021, 16546475.
34. Zee RY, Germer S, Thomas A, Raji A, Rhees B, Ridker PM, et al. C-reactive protein gene variation and type 2 diabetes mellitus: a case-control study. Atherosclerosis 2008, 197:931-936. 10.1016/j.atherosclerosis.2007.08.013, 17900590.
35. Lange LA, Burdon K, Langefeld CD, Liu Y, Beck SR, Rich SS, et al. Heritability and expression of C-reactive protein in type 2 diabetes in the Diabetes Heart Study. Ann Hum Genet 2006, 70:717-725. 10.1111/j.1469-1809.2006.00280.x, 17044846.
36. Wakefield J, De VF, Hung RJ. Bayesian mixture modeling of gene-environment and gene-gene interactions. Genet Epidemiol 2010, 34:16-25. 2796715, 19492346.
37. The International HapMap Project. Nature 2003, 426:789-796. 10.1038/nature02168, 14685227.
38. Mucci LA, Hsieh CC, Williams PL, Dickman PW, Bjorkman L, Pedersen NL. Birth order, sibship size, and housing density in relation to tooth loss and periodontal disease: a cohort study among Swedish twins. Am J Epidemiol 2004, 159:499-506. 10.1093/aje/kwh063, 14977646.
39. Narum SR. Beyond Bonferroni: Less conservative analyses for conservation genetics. Conservation Genetics 2006, 7:783-787.
40. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334. 10.1001/jama.286.3.327, 11466099.
41. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137. 10.2337/diabetes.51.4.1131, 11916936.
42. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003, 163:93-99. 10.1001/archinte.163.1.93, 12523922.
43. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007, 30:854-860. 10.2337/dc06-1693, 17392546.
44. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007, 65:S152-S156. 10.1301/nr.2007.dec.S152-S156, 18240540.
45. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986. 10.1001/jama.291.16.1978, 15113816.
46. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Keen LJ, Laundy GJ. Human cytokine gene nucleotide sequence alignments: supplement 1. Eur J Immunogenet 1999, 26:135-223. 10.1046/j.1365-2370.1999.00143.x-i2, 10331159.
47. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002, 3:313-330. 10.1038/sj.gene.6363881, 12209358.
48. Hollegaard MV, Bidwell JL. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006, 7:269-276. 10.1038/sj.gene.6364301, 16642032.
49. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999, 1:3-19. 10.1038/sj.gene.6363645, 11197303.
50. Ollier WE. Cytokine genes and disease susceptibility. Cytokine 2004, 28:174-178. 10.1016/j.cyto.2004.07.014, 15588692.
51. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399. 10.1016/S0161-5890(97)00052-7, 9293772.
52. Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res 1994, 22:1108-1114. 10.1093/nar/22.6.1108, 307937, 8152914.
53. Mangangcha IR, Jha P, Arora K, Mukerji M, Banavaliker JN, et al. Differential serum cytokine levels are associated with cytokine gene polymorphisms in north Indians with active pulmonary tuberculosis. Infect Genet Evol 2011,
54. Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1?. Ann N Y Acad Sci 1995, 762:102-107.
55. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002, 53:1029-1034. 10.1016/S0008-6363(01)00534-X, 11922913.
56. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006, 59:211-215. 10.1136/jcp.2004.025452, 1860309, 16443741.
57. Paik JK, Kim OY, Koh SJ, Jang Y, Chae JS, Kim JY, et al. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors. Clin Chim Acta 2007, 380:68-74. 10.1016/j.cca.2006.11.011, 17335789.
58. Kathiresan S, Manning AK, Demissie S, D'Agostino RB, Surti A, Guiducci C, et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S17. 10.1186/1471-2350-8-S1-S17, 1995614, 17903299.
59. Palmer ND, Langefeld CD, Ziegler JT, Hsu F, Haffner SM, Fingerlin T, et al. Candidate loci for insulin sensitivity and disposition index from a genome-wide association analysis of Hispanic participants in the Insulin Resistance Atherosclerosis (IRAS) Family Study. Diabetologia 2010, 53:281-289. 10.1007/s00125-009-1586-2, 2809812, 19902172.
60. Benjamin EJ, Dupuis J, Larson MG, Lunetta KL, Booth SL, Govindaraju DR, et al. Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S11. 10.1186/1471-2350-8-S1-S11, 1995615, 17903293.
61. Wakefield J. Bayes factors for genome-wide association studies: comparison with P-values. Genet Epidemiol 2009, 33:79-86. 10.1002/gepi.20359, 18642345.
62. Vallianou NG, Evangelopoulos AA, Panagiotakos DB, Georgiou AT, Zacharias GA, Vogiatzakis ED, et al. Associations of acute-phase reactants with metabolic syndrome in middle-aged overweight or obese people. Med Sci Monit 2010, 16:CR56-CR60.
63. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target?. Can J Cardiol 2010, 26(Suppl A):41A-44A.
64. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119. 1087185, 15864338.
65. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801. 10.1172/JCI29069, 1483173, 16823477.